01

Daxdilimab Cuts Disease Activity in Moderate-to-Severe Discoid Lupus

Phase 2 data show daxdilimab reduced disease activity in moderate-to-severe discoid lupus, a cutaneous lupus subtype with few targeted treatment options available.